- Home
- CPZ vs IMMP Comparison
CPZ vs IMMP Comparison
Compare CPZ & IMMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CPZ
- IMMP
- Stock Information
- Founded
- CPZ 2019
- IMMP 1987
- Country
- CPZ United States
- IMMP Australia
- Employees
- CPZ N/A
- IMMP N/A
- Industry
- CPZ Trusts Except Educational Religious and Charitable
- IMMP Biotechnology: Pharmaceutical Preparations
- Sector
- CPZ Finance
- IMMP Health Care
- Exchange
- CPZ Nasdaq
- IMMP Nasdaq
- Market Cap
- CPZ 300.6M
- IMMP 304.0M
- IPO Year
- CPZ N/A
- IMMP N/A
- Fundamental
- Price
- CPZ $15.70
- IMMP $1.85
- Analyst Decision
- CPZ
- IMMP Buy
- Analyst Count
- CPZ 0
- IMMP 2
- Target Price
- CPZ N/A
- IMMP $8.50
- AVG Volume (30 Days)
- CPZ 63.0K
- IMMP 74.2K
- Earning Date
- CPZ 01-01-0001
- IMMP 03-25-2025
- Dividend Yield
- CPZ 11.07%
- IMMP N/A
- EPS Growth
- CPZ N/A
- IMMP N/A
- EPS
- CPZ N/A
- IMMP N/A
- Revenue
- CPZ N/A
- IMMP $3,019,249.00
- Revenue This Year
- CPZ N/A
- IMMP N/A
- Revenue Next Year
- CPZ N/A
- IMMP $20.28
- P/E Ratio
- CPZ N/A
- IMMP N/A
- Revenue Growth
- CPZ N/A
- IMMP 24.11
- 52 Week Low
- CPZ $13.17
- IMMP $1.65
- 52 Week High
- CPZ $16.11
- IMMP $3.34
- Technical
- Relative Strength Index (RSI)
- CPZ 61.97
- IMMP 48.75
- Support Level
- CPZ $15.12
- IMMP $1.65
- Resistance Level
- CPZ $15.68
- IMMP $1.88
- Average True Range (ATR)
- CPZ 0.23
- IMMP 0.09
- MACD
- CPZ 0.03
- IMMP 0.01
- Stochastic Oscillator
- CPZ 93.55
- IMMP 65.00
About CPZ Calamos Long/Short Equity & Dynamic Income Trust
Calamos L/S Equity & Dynamic Inc Trust is a trust company which seeks to provide current income and risk-managed capital appreciation. The company invests in securities across sectors such as Industrials, Healthcare, Financials, Consumer Discretionary and others.
About IMMP Immutep Limited
Immutep Ltd is a globally active biotechnology company developing immunotherapy products for cancer and autoimmune diseases. Its main product is IMP321, which involves clinical development for the treatment of cancer indications. The company is also focused on the development of other products, which include IMP701, which is a blocking anti-LAG-3 antibody for cancer and is in Phase I of its clinical trials, and CVac, which is a personalized immunocellular therapeutic investigated for the treatment of epithelial cancer. Geographically all the business activity of the firm is functioned through the region of Australia.